الفعالية العلاجية لمركب FLUDARABINE في معالجة مرضى CLL المعندين على المعالجة

Authors

  • سهام سليمان

Abstract

يهدف هذا البحث إلى دراسة فعالية مركب Fludarabine في علاج الابيضاض اللمفاوي المزمن المعند  على العلاجات الأخرى، ودراسة اختلاطات استخدام هذا المركب على المرضى.

أعطيت هذه المعالجة لـ 19 مريضاً شخص لهم CLL، ولم يحققوا أية استجابة على العلاجات الأخرى بجرعة 25 مغ/م2 تسريب وريدي لمدة نصف ساعة يومياً ولمدة 5 أيام يعاد الشوط كل 4 أسابيع (3-6 أشواط). تمت متابعة المرضى سريرياً ومخبرياً كل شهر مرة مع تقييم نقوي كل 3 أشهر.

بنتيجة هذه المعالجة حصل 21% من المرضى على هوادة تامة و 47,36% على هوادة جزئية. استمرت الهوادة التامة 9 أشهر وسطياً ووسطي الحياة 42 شهرا . وكان التثبيط النقوي أهم اختلاطات المعالجة المشاهدة.

The research aims to study the activity of Fludarabine in the treatment of refractory CLL, and its side effects.

Nineteen patients were included in this study, all of whom had been previously treated with another treatment without success. The doses were 25 mg/m2 once daily, 5 days every 4 weeks (3-6 times). Patients were evaluated before treatment, observed during treatment with monthly blood evaluation, three-monthly, bone marrow evaluation, in addition to clinical follow up.

Hematological improvement was observed with complete remission in 4 patients (21%). Partial remission was seen in 9 patients (47.36%) after 6 months of treatment. The CR kept of 9 months. The major complication was bone marrow suppression.

Downloads

Published

2019-01-14

How to Cite

1.
سليمان س. الفعالية العلاجية لمركب FLUDARABINE في معالجة مرضى CLL المعندين على المعالجة. Tuj-hlth [Internet]. 2019Jan.14 [cited 2024May9];27(1). Available from: https://journal.tishreen.edu.sy/index.php/hlthscnc/article/view/6318

Issue

Vol. 27 No. 1 (2005): العلوم الصحية

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series

 Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series   .  The Readers have the right to send, print and subscribe to the initial version of the article, and the title of  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series  Publisher

journal uses a CC BY-NC-SA license which mean

You are free to:

  • Adapt — remix, transform, and build upon the material
  •  
  • The licensor cannot revoke these freedoms as long as you follow the license terms.

 

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • NonCommercial — You may not use the material for commercial purposes.
  • ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.